4D Molecular Therapeutics, Inc. (FDMT)
Market Cap | 1.06B |
Revenue (ttm) | 20.45M |
Net Income (ttm) | -104.56M |
Shares Out | 51.70M |
EPS (ttm) | -2.44 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 386,749 |
Open | 21.28 |
Previous Close | 21.34 |
Day's Range | 20.42 - 21.60 |
52-Week Range | 9.44 - 36.25 |
Beta | 2.88 |
Analysts | Strong Buy |
Price Target | 48.25 (+134.45%) |
Earnings Date | Aug 7, 2024 |
About FDMT
4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macul... [Read more]
Financial Performance
In 2023, FDMT's revenue was $20.72 million, an increase of 562.29% compared to the previous year's $3.13 million. Losses were -$100.84 million, -6.19% less than in 2022.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for FDMT stock is "Strong Buy." The 12-month stock price forecast is $48.25, which is an increase of 134.45% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/y/f/press16-2469881.jpg)
4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting
EMERYVILLE, Calif., June 08, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full po...
![](https://cdn.snapi.dev/images/v1/m/x/press13-2465775.jpg)
4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference
EMERYVILLE, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full po...
![](https://cdn.snapi.dev/images/v1/p/z/conf17-2453449.jpg)
4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47ᵗʰ European Cystic Fibrosis Conference
EMERYVILLE, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full pot...
![](https://cdn.snapi.dev/images/v1/a/y/press10-2422566.jpg)
4DMT Reports First Quarter 2024 Financial Results and Operational Highlights
EMERYVILLE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full pot...
![](https://cdn.snapi.dev/images/v1/o/c/conf9-2414477.jpg)
4DMT to Participate in Upcoming Investor Conference
EMERYVILLE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full pot...
![](https://cdn.snapi.dev/images/v1/l/t/press6-2402533.jpg)
4DMT Announces Presentations at ARVO 2024 Annual Meeting
EMERYVILLE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full pot...
![](https://cdn.snapi.dev/images/v1/m/u/press2-2345962.jpg)
4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
EMERYVILLE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full p...
![](https://cdn.snapi.dev/images/v1/b/n/conf15-2306059.jpg)
4DMT to Participate in Upcoming Investor Conferences
EMERYVILLE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full p...
![](https://cdn.snapi.dev/images/v1/w/m/press3-2302241.jpg)
4DMT Reports Full Year 2023 Financial Results and Operational Highlights
EMERYVILLE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full po...
![](https://cdn.snapi.dev/images/v1/t/y/press7-2271257.jpg)
4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024
EMERYVILLE, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full po...
![](https://cdn.snapi.dev/images/v1/j/h/press6-2263697.jpg)
4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
EMERYVILLE, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a leading clinical-stage genetic medicines company focused on unlocking the full potential of gene...
![](https://cdn.snapi.dev/images/v1/z/a/press4-2260781.jpg)
4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
EMERYVILLE, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a leading clinical-stage genetic medicines company focused on unlocking the full potential of gene...
![](https://cdn.snapi.dev/images/v1/b/a/bank10-2260541.jpg)
4D Molecular soars as mid-stage data for eye disease therapy 'checks all boxes'
Shares of 4D Molecular Therapeutics more than doubled on Monday after the therapy developer reported results from a mid-stage trial of its eye disease therapy.
![](https://cdn.snapi.dev/images/v1/y/m/press11-2258942.jpg)
4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD
EMERYVILLE, Calif., Feb. 03, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full po...
![](https://cdn.snapi.dev/images/v1/p/m/conf13-2248530.jpg)
4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden
EMERYVILLE, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full po...
![](https://cdn.snapi.dev/images/v1/y/x/press19-2240029.jpg)
4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease
EMERYVILLE, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full po...
![](https://cdn.snapi.dev/images/v1/i/8/press14-2216212.jpg)
4DMT Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates
EMERYVILLE, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full po...
![](https://cdn.snapi.dev/images/v1/q/o/press4-2214534.jpg)
4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases
EMERYVILLE, Calif. and CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT), a leading clinical-stage genetic medicines company focused on unlocking the f...
![](https://cdn.snapi.dev/images/v1/d/n/press12-2204844.jpg)
4DMT Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD, the First RMAT Designation in Wet AMD
EMERYVILLE, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full po...
![](https://cdn.snapi.dev/images/v1/f/7/conf8-2181702.jpg)
4DMT to Present Interim 24 Week Data from Randomized Phase 2 PRISM Clinical Trial of 4D-150 in High Treatment Need Wet AMD Patients at Angiogenesis, Exudation, and Degeneration 2024 Conference
EMERYVILLE, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a clinical-stage biotherapeutics company with three novel, highly targeted next gen...
![](https://cdn.snapi.dev/images/v1/x/h/press3-2151126.jpg)
4DMT Reports Third Quarter 2023 Financial Results and Operational Highlights
EMERYVILLE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT, or the Company) a genetic medicines company with three novel, highly targeted next generation AAV v...
![](https://cdn.snapi.dev/images/v1/h/x/press15-2134112.jpg)
4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Cystic Fibrosis at 2023 NACFC
EMERYVILLE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT, or the Company), a genetic medicines company with three novel, highly targeted next generation AAV ...
![](https://cdn.snapi.dev/images/v1/k/s/press10-2127693.jpg)
4DMT Gains Alignment with FDA on Plan to Lift Clinical Hold on Phase 1/2 INGLAXA Clinical Trial for 4D-310 for Fabry Disease Cardiomyopathy
EMERYVILLE, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a clinical-stage genetic medicines company with three novel, highly targeted next g...
![](https://cdn.snapi.dev/images/v1/u/y/conf17-2119499.jpg)
4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 2023 NACFC
EMERYVILLE, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a clinical-stage genetic medicines company with three novel, highly targeted next ...
![](https://cdn.snapi.dev/images/v1/p/r/press14-2115005.jpg)
4DMT Receives EMA Priority Medicines (PRIME) Designation for 4D-150 Clinical-Stage Genetic Medicine for Treatment of Wet AMD
EMERYVILLE, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a clinical-stage biotherapeutics company with three novel, highly targeted next gen...